The therapeutic implications are broad: pharmacologic blockade of FATP2 with compounds such as lipofermata can protect parenchymal tissues like the kidney and liver from lipid overload, while also reprogramming the tumor microenvironment by disarming immunosuppressive MDSCs (9, 13, 14). Here, SLC27A2 is linked to neoplasm.